Results 271 to 280 of about 42,993 (314)
Some of the next articles are maybe not open access.
Muscarinic Antagonists for Myopia Control
1998Previous nonsurgical treatment of myopia using optical and pharmaceutical agents has not allowed an unequivocal consensus. Such studies must be based on the natural history of myopia progression, accurate biometric measurements, and randomized clinical trials.
Sek-Jin Chew +3 more
openaire +1 more source
Affinitu profile of the novel muscarinic antagonist guanylpirenzepine
Life Sciences, 1990The study reports the functional affinity of an amidino derivative of pirenzepine, guanylpirenzepine, for muscarinic receptors mediating relaxation of rat duodenum, inhibition of rabbit vas deferens twitch contraction (both receptors previously classified as M1), guinea pig negative inotropism (M2) and ileal contraction (M3).
R, Micheletti +6 more
openaire +2 more sources
Muscarinic agonists and antagonists in the treatment of Alzheimer's disease
Il Farmaco, 2001Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and personality changes. The development of drugs for the treatment of the cognitive deficits of AD has focused on agents which counteract loss in cholinergic activity. Although symptoms of AD have been successfully treated with acetylcholinesterase inhibitors
W, Greenlee +23 more
openaire +2 more sources
MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER
BJU International, 2000ABSTRACT A wealth of clinical evidence supports the view that muscarinic receptor antagonists are effective in the treatment of overactive bladder. However, treatment‐limiting adverse effects such as dry mouth, constipation, and blurred vision have restricted the usefulness of previously available agents, such as ...
openaire +2 more sources
Role of muscarinic receptor antagonists in urgency and nocturia
BJU International, 2005The overactive bladder (OAB) syndrome is defined as urgency, with or without urgency incontinence, usually accompanied by frequency and nocturia. Muscarinic receptor antagonists are the most established form of treatment for OAB, but until recently their effectiveness was only confirmed for symptoms of incontinence and frequency.
Martin C, Michel +1 more
openaire +2 more sources
A study of muscarinic receptor heterogeneity with weak antagonists
European Journal of Pharmacology, 1976A study of heterogeneity among muscarinic receptors was carried out with new rigid molecules, comprising structures in the fused quinuclidine-valerolactone, quinuclidine-cyclohexenone, quinuclidine-cyclohexanone and quinuclidine-cyclohexane derivatives.
A, Fisher +4 more
openaire +2 more sources
Identification and characterization of m4 selective muscarinic antagonists
Bioorganic & Medicinal Chemistry Letters, 1997Our interest in the area of m4 muscarinic antagonists had led us to study a series of benzoxazine isoquinolines. One of the most potent and selective compounds of this series is example 1 with an IC50 value of 90.7 nM at m4 receptors, and 72-fold (m1), 38-fold (m2), 10-fold (m3), and 82-fold (m5) more selective compared to the other receptors.
C E, Augelli-Szafran +5 more
openaire +2 more sources
Selective muscarinic receptor antagonists for airway diseases
Current Opinion in Pharmacology, 2001Airway tone and airway hyperreactivity are mediated by the parasympathetic nerves that release acetylcholine onto muscarinic receptors (M1-M5). Stimulation of M1 and M3 muscarinic receptors causes bronchoconstriction. The M1 muscarinic receptor is excitatory, and facilitates neuronal transmission at the parasympathetic ganglion.
A M, Lee, D B, Jacoby, A D, Fryer
openaire +2 more sources
Muscarinic Receptor Subtypes and the Selectivity of Agonists and Antagonists
Pharmacology, 1988Receptors may be grouped into superfamilies, according to their mechanism. Muscarinic receptors belong to one such superfamily, that of the G-protein coupled receptors. Subtypes of muscarinic receptors may be defined according to their primary amino acid sequence, their mechanism and their pharmacology.
N J, Birdsall +6 more
openaire +2 more sources
A COMPARISON OF THE MUSCARINIC ANTAGONIST ACTIONS OF PANCURONIUM AND ALCURONIUM
Journal of Autonomic Pharmacology, 1982In the pithed rat, muscarine (2.5–10μg/kg i.v.) normally produced bradycardias, but tachycardias were seen in the presence of pancuronium (0.1–1.0mg/kg i.v.) and alcuronium (0.1–5.0mg/kg i.v.). The tachycardia was probably a result of muscarinic receptor stimulation, because it was antagonized by atropine (10μg/kg i.v.) and pirenzepine (10–30μg/kg i ...
D W, Dalton, M B, Tyers
openaire +2 more sources

